The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets
10.18632/oncotarget.8775
Saved in:
| Main Authors: | , |
|---|---|
| 其他作者: | |
| 格式: | Review |
| 出版: |
Impact Journals LLC
2020
|
| 主題: | |
| 在線閱讀: | https://scholarbank.nus.edu.sg/handle/10635/180389 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|
| id |
sg-nus-scholar.10635-180389 |
|---|---|
| record_format |
dspace |
| spelling |
sg-nus-scholar.10635-1803892024-11-10T00:39:33Z The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets Chong, D.Q Zhu, A.X DUKE-NUS MEDICAL SCHOOL B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib epidermal growth factor receptor FGFR2 protein, human fibroblast growth factor receptor 2 isocitrate dehydrogenase MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct carcinoma bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor 10.18632/oncotarget.8775 Oncotarget 7 29 46750-46767 2020-10-26T08:46:01Z 2020-10-26T08:46:01Z 2016 Review Chong, D.Q, Zhu, A.X (2016). The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets. Oncotarget 7 (29) : 46750-46767. ScholarBank@NUS Repository. https://doi.org/10.18632/oncotarget.8775 1949-2553 https://scholarbank.nus.edu.sg/handle/10635/180389 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ Impact Journals LLC Unpaywall 20201031 |
| institution |
National University of Singapore |
| building |
NUS Library |
| continent |
Asia |
| country |
Singapore Singapore |
| content_provider |
NUS Library |
| collection |
ScholarBank@NUS |
| topic |
B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib epidermal growth factor receptor FGFR2 protein, human fibroblast growth factor receptor 2 isocitrate dehydrogenase MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct carcinoma bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor |
| spellingShingle |
B Raf kinase bevacizumab biological marker bortezomib cabozantinib capecitabine cediranib ceritinib cetuximab cisplatin dasatinib epidermal growth factor receptor erlotinib fibroblast growth factor receptor 2 gemcitabine hybrid protein irinotecan isocitrate dehydrogenase K ras protein lapatinib oxaliplatin panitumumab ponatinib protein p53 selumetinib sorafenib sunitinib tivantinib unindexed drug vandetanib epidermal growth factor receptor FGFR2 protein, human fibroblast growth factor receptor 2 isocitrate dehydrogenase MET protein, human programmed death 1 receptor scatter factor receptor vasculotropin receptor advanced cancer bile duct carcinoma biliary tract cancer cancer combination chemotherapy cancer incidence cancer patient cancer prognosis cancer survival drug targeting epithelium cell exome gene mutation hepatobiliary system human liver cancer liver cell carcinoma metastasis molecularly targeted therapy next generation sequencing nonhuman Review somatic mutation antagonists and inhibitors bile duct carcinoma bile duct tumor gene fusion genetics mutation Bile Duct Neoplasms Cholangiocarcinoma Gene Fusion Humans Isocitrate Dehydrogenase Molecular Targeted Therapy Mutation Programmed Cell Death 1 Receptor Proto-Oncogene Proteins c-met Receptor, Epidermal Growth Factor Receptor, Fibroblast Growth Factor, Type 2 Receptors, Vascular Endothelial Growth Factor Chong, D.Q Zhu, A.X The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets |
| description |
10.18632/oncotarget.8775 |
| author2 |
DUKE-NUS MEDICAL SCHOOL |
| author_facet |
DUKE-NUS MEDICAL SCHOOL Chong, D.Q Zhu, A.X |
| format |
Review |
| author |
Chong, D.Q Zhu, A.X |
| author_sort |
Chong, D.Q |
| title |
The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets |
| title_short |
The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets |
| title_full |
The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets |
| title_fullStr |
The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets |
| title_full_unstemmed |
The landscape of targeted therapies for cholangiocarcinoma: Current status and emerging targets |
| title_sort |
landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets |
| publisher |
Impact Journals LLC |
| publishDate |
2020 |
| url |
https://scholarbank.nus.edu.sg/handle/10635/180389 |
| _version_ |
1821186665645867008 |